Table 1.
Baseline characteristics of patients
| Characteristic | N = 15 |
|---|---|
| Median age, years (range) | 61 (40–79) |
| Male/female, n (%) | 5/10,50 |
| Disease stage, n (%) | |
| IIIc | 7 (47) |
| IV M1a | 0 (0) |
| IV M1b | 0 (0) |
| IV M1c | 8 (53) |
| ECOG PS, n (%) | |
| 0 | 15 (100) |
| 1 | 0 |
| Tumor subtype, n (%) | |
| Cutaneous | 14 (93) |
| Mucosal | 0 (0) |
| Ocular | 1 (7) |
| Unknown | 0 (0) |
| Baseline LDH, n (%) | |
| Elevated | 4 (27) |
| Normal | 11(73) |
| BRAFV600 mutation positive, n/n (%) | 4/15 (27) |
| NRASQ61R mutation positive, n/n (%) | 1/15 (7) |
| BRAF/NRAS WT, n/n (%) | 10/15 (66) |
ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase.